About Us

Cytox Limited is a UK-based company with a unique scientific and proprietary technology platform. Through the application of this fundamental science and our specific know-how, we are elucidating the biology and genetics behind dementia, as well as developing prognostics tests for cognitive decline and individual risk of developing AD or other dementias.

Contact us to find out more about our plans and how you could work with us.

The business and science team is supported by an experienced Board of Directors:


Dr Richard Pither, CEO
Richard Pither has been involved in the development of diagnostic and therapeutic pharmaceutical products for more than 20 years. He has held senior R&D and leadership positions in global Pharmaceutical companies including GE Healthcare (Medical Diagnostics), UCB-Celltech, Lorantis and Amersham plc. During this time, he was involved in the development of a novel 18F-PET radiopharmaceutical for imaging amyloid deposition in the brains of Alzheimer’s disease patients.

Dr David Whitcombe, Non-executive Director
David Whitcombe is a Venture Partner with Catapult Ventures, having worked alongside Catapult and its portfolio companies for a number of years informally. He has a wealth of experience in diagnostics and molecular biology and understands what it takes to grow a successful life science business. David co-founded DxS Diagnostics in 2000 to expand upon technology he developed at AstraZeneca, and sold the company in 2009 to Qiagen for in excess of £100m.


Dr Andrew Carr, Chairman
Andrew has already worked with Cytox in an advisory capacity and brings a wealth of highly relevant experience from both large companies (Amersham Biosciences; GE Healthcare; Thermo Fisher Scientific) and smaller biotechs (Teraview; deltaDOT; Akubio, BAC B.V).

Back to Top